poisar

Stock

Viridian Therapeutics, Inc. VRDN

$23.89-1.53%

Overview

VRDN market data

Price History

VRDN price chart · 1M
O
23.98
H
24.25
L
23.82
C
23.89
Vol
67,074.00
Source
US equities market feed
Observed
Aug 27, 2026, 12:00 AM
Cadence
Five-minute page cache; daily and stored hourly bars
Status
fresh

Key Stats & Performance

Open
$23.98
Previous Close
$24.26
Day High
$24.25
Day Low
$23.82
52 Week High
$24.85
52 Week Low
$13.18
7 Day Return
-2.53%
30 Day Return
+22.45%
90 Day Return
+35.55%
1 Year Return
+79.62%
Daily Notional Volume
$1.6M
Latest daily bar volume multiplied by its closing price.

Valuation & Profitability

Provider-backed
P/E (TTM)
Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
Forward P/E
P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
EPS (TTM)
-$4.04
Diluted earnings per share over the trailing twelve months.
Beta
1.10
Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
Dividend Yield
Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
Profit Margin
-544.1%
Net income divided by revenue. Comparable within a sector, less so across sectors.
52w range
$13.18 – $34.29
Lowest and highest closing prices over the past 52 weeks.
Analyst Target
Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.

Display-only. Refreshed once per symbol per 24 hours · market cap $2.5B · P/B 4.11 · P/S 34.80.

Company News

10 captured
RBC Capital Maintains Outperform on Viridian Therapeutics, Raises Price Target to $36Benzinga · Aug 7, 2026, 8:25 PM
Truist Securities Maintains Buy on Viridian Therapeutics, Raises Price Target to $39Benzinga · Aug 7, 2026, 1:27 PM
Viridian Therapeutics shares are trading higher after the company reported better-than-expected Q2 sales results.Benzinga · Aug 6, 2026, 7:50 PM
Viridian Therapeutics Q2 EPS $(1.05) Misses $(1.02) Estimate, Sales $233.000K Beat $22.308K EstimateBenzinga · Aug 6, 2026, 11:50 AM
8-K filing — Viridian Therapeutics, Inc.\DE (VRDN)SEC EDGAR · Aug 6, 2026, 11:05 AM
RBC Capital Maintains Outperform on Viridian Therapeutics, Raises Price Target to $35Benzinga · Jun 30, 2026, 3:40 PM
Truist Securities Maintains Buy on Viridian Therapeutics, Raises Price Target to $38Benzinga · Jun 30, 2026, 2:00 PM
Wedbush Maintains Outperform on Viridian Therapeutics, Raises Price Target to $43Benzinga · Jun 30, 2026, 12:50 PM
Wells Fargo Upgrades Viridian Therapeutics to Overweight, Raises Price Target to $31Benzinga · Jun 29, 2026, 5:00 PM
Viridian Secures First FDA Approval, Sets Up Challenge To Amgen's Tepezza For Thyroid Eye DiseaseBenzinga · Jun 29, 2026, 1:25 PM

Decision & Score

Members

Our Tradable / Watch / Avoid decision and 0–100 conviction score for this symbol are members-only.

Create account to unlock

Trend & Pattern Evidence

Members

Trend alignment and backtested chart-pattern probabilities are members-only.

Create account to unlock

Sector Peer Ranking

Members

Ranked sector peers with scores and decisions are members-only.

Create account to unlock